Emerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering
04 août 2020 18h32 HE
|
Emerald Bioscience, Inc.
Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering
31 juil. 2020 09h20 HE
|
Emerald Bioscience, Inc.
Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting
09 juin 2020 09h37 HE
|
Emerald Bioscience, Inc.
Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of...
Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in Japan
02 juin 2020 08h30 HE
|
Emerald Bioscience, Inc.
Long Beach, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications,...
Emerald Bioscience Joins Alliance for Biosecurity
08 avr. 2020 08h30 HE
|
Emerald Bioscience, Inc.
The Alliance is a government-industry consortium that is a leading voice on biosecurity issues in the United States Long Beach, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience,...
Emerald Bioscience Announces Notice of Allowance from United States Patent Office for Proprietary Analog of Cannabidiol
09 mars 2020 08h30 HE
|
Emerald Bioscience, Inc.
Long Beach, California, March 09, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI”), focused on the development of cannabinoid-based therapeutics to address global medical...